A second biopsy was gathered from a mCRC patient whose tumour carried genetic alterations in RNF43 and BRAF genes, and clinically responded and then relapsed to EGFR blockade with cetuximab in combination with the BRAF inhibitor encorafenib. The gene discussed is BRAF; the disease is neoplasm.